Guillain-Barré syndrome pathophysiology

Guillain-Barré syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Guillain-Barré syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural history, Complications, and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Guillain-Barré syndrome pathophysiology On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Guillain-Barré syndrome pathophysiology All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Guillain-Barré syndrome pathophysiology
CDC on Guillain-Barré syndrome pathophysiology
Guillain-Barré syndrome pathophysiology in the news
Blogs on Guillain-Barré syndrome pathophysiology
Directions to Hospitals Treating Guillain-Barré syndrome
Risk calculators and risk factors for Guillain-Barré syndrome pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Priyamvada Singh, MBBS [2]

Overview

Guillain-Barré syndrome (GBS) is an acute, autoimmune, polyradiculoneuropathy affecting the peripheral nervous system, usually triggered by an acute infectious process. It involves an auto-immune mechanism in which the antibodies formed against the lipopolysaccharides of bacteria or certain vaccines cross reacts with the gangliosides present in myelin of peripheral nerves. As a result of which, myelin degeneration occurs leading to conduction defects that manifests as flaccid paralysis.

Pathophysiology

• GBS is often associated with an antecedent infection with agents such as Campylobacter jejuni or exposure to some vaccines (influenza vaccine).

• These causative agents have certain lipopolysaccharides antigens in their capsules that are similar to gangliosides and glycolipids, such as GM1 and GD1b found in myelin tissues of the peripheral nerve.

• The immune responses directed against these bacterial capsular lipopolysaccharides also targets the similar GM1 ganglioside which are complex glycosphingolipids present in large quantities on human nerve tissues, especially in the nodes of Ranvier. An example is the GM1 ganglioside, which can be affected in as many as 20-50% of cases, especially in those preceded by Campylobacter jejuni infections. Another example is the GQ1b ganglioside, which is the target in the Miller Fisher syndrome variant.

• Cellular and humoral immune mechanisms play an important role in the development of disease. Pathologic findings in GBS include lymphocytic infiltration of peripheral nerves, followed by macrophage-mediated, multifocal attack of myelin.

• These type of immune response that are primarily for foreign antigens (such as infectious agents or vaccines) but are mis-targeted to host nerve tissues instead are called antigenic mimicry or molecular mimicry.

• The end result of such autoimmune attack on the peripheral nerves is inflammation of myelin, defects in the propagation of electrical nerve impulses and conduction block, leading to a muscle paralysis that may be accompanied by sensory or autonomic disturbances.

• However, in mild cases, axonal function remains intact and recovery can be rapid if remyelination occurs.

• In severe cases, such as in the AMAN or AMSAN variants, axonal degeneration occurs, and recovery depends on axonal regeneration. Recovery becomes much slower, and there is a greater degree of residual damage.

• Recent studies on the disease have demonstrated that approximately 80% of the patients have myelin loss, whereas, in the remaining 20%, the pathologic hallmark of the disease is indeed axon loss.

{{#ev:youtube|i_jsTpiR8rw&feature}}

Physiology

The normal physiology of [name of process] can be understood as follows:

Pathogenesis

• The exact pathogenesis of [disease name] is not completely understood.

OR

• It is understood that [disease name] is the result of / is mediated by / is produced by / is caused by either [hypothesis 1], [hypothesis 2], or [hypothesis 3].
• [Pathogen name] is usually transmitted via the [transmission route] route to the human host.
• Following transmission/ingestion, the [pathogen] uses the [entry site] to invade the [cell name] cell.
• [Disease or malignancy name] arises from [cell name]s, which are [cell type] cells that are normally involved in [function of cells].
• The progression to [disease name] usually involves the [molecular pathway].
• The pathophysiology of [disease/malignancy] depends on the histological subtype.

Genetics

[Disease name] is transmitted in [mode of genetic transmission] pattern.

OR

Genes involved in the pathogenesis of [disease name] include:

• [Gene1]
• [Gene2]
• [Gene3]

OR

The development of [disease name] is the result of multiple genetic mutations such as:

• [Mutation 1]
• [Mutation 2]
• [Mutation 3]

Associated Conditions

Conditions associated with [disease name] include:

• [Condition 1]
• [Condition 2]
• [Condition 3]

Gross Pathology

On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Microscopic Pathology

On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].